ABCB1 p.Glu255Lys
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 20720558
[PubMed]
Takahashi N et al: "Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia."
No.
Sentence
Comment
24
In patients without a CCyR, mutation analysis of the bcr-abl fusion transcript was performed using the Invader assay,31 which detects 25 mutations, including M244V, L248VR, G250E, Q252H, Q252R, Y253F, Y253H, E255K, E255V, E279K, F311L, T315A, T315I, F317L, M351T, F359IV, V379I, L387M, H396P, H396R, S417Y, E459K and F486S.
X
ABCB1 p.Glu255Lys 20720558:24:208
status: NEW
PMID: 23788109
[PubMed]
Koldehoff M et al: "Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells."
No.
Sentence
Comment
92
Additive effects of co-transfection with BCR-ABL siRNA and GFI1B siRNA in primary CML cells In order to verify the above-described antileukemic effects, we assessed BCR-ABL siRNA and GFI1B siRNA transfection in primary cells obtained from four patients with BC of CML (patients with Y253F; F317L; and E255K mutation, and one patient with TKI resistant CML).
X
ABCB1 p.Glu255Lys 23788109:92:301
status: NEW